1 / 11

Welcome and Introduction

Welcome and Introduction. Moderator: John Bartlett, MD Discussants: Cal Cohen, MD Ian Frank, MD . Accreditation Statement.

Leo
Download Presentation

Welcome and Introduction

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Welcome and Introduction Moderator: John Bartlett, MD Discussants: Cal Cohen, MD Ian Frank, MD

  2. Accreditation Statement The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Statement:The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. To obtain CME credit, on the home page of this program under the heading “Instructions for Obtaining Continuing Medical Education Credit” there is a “CME Post Test and Evaluation” link that take you to the CME test.

  3. This program is made possible through an educational grant from Merck & Co., Inc.

  4. Program Objectives At the conclusion of this activity the participant should be able to: Integrate and discuss the clinical use and balancing of drug, regimen and patient characteristics that have been demonstrated in clinical trials to be predictive of ARV treatment success. Analyze current clinical trial data on treatment of ARV-naïve and ARV-experienced patients and use this information to select ARV drugs and regimens that maximize the chance for virologic success, avoidance of toxicity and long-term adverse events and minimize the risk of loss of future treatment options. Incorporate into clinical decisions the differences between various classes of ARVs, and different ARV agents within classes, regarding virologic and immunologic efficacy, safety and likelihood of resistance. Describe and explain the key new clinical trials on ARV therapy and ARV therapy strategies presented at the 16th CROI.

  5. Course Directors John Bartlett, MDProfessor of MedicineJohns Hopkins School of MedicineBaltimore, Maryland Calvin J. Cohen, MD, MSResearch Director, CRI New EnglandClinical Instructor, Harvard Medical SchoolBoston, Massachusetts

  6. Faculty Rafael E. Campo, MDUniversity of Miami School of MedicineMiami, Florida Eric Daar, MDDavid Geffen School of Medicine at UCLALos Angeles, California Edwin DeJesus, MDOrlando Immunology CenterOrlando, Florida Richard A. Elion, MDGeorge Washington University Medical CenterWashington, DC Ian Frank, MDUniversity of Pennsylvania Philadelphia, Pennsylvania Trevor Hawkins, MDSouthwest CARE CenterSanta Fe, New Mexico Graeme J. Moyle, MD, MB, BSChelsea & Westminster HospitalLondon, England Paul Sax, MDHarvard Medical SchoolBoston, Massachusetts Luther A. Virgil, Jr., MDNational Minority ClinicalResearch AssociationFairfield, New Jersey

  7. Disclosures As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturers of any commercial products discussed in an educational presentation. The disclosures of the faculty for this program can be found in your handout materials and are presented in the following slides:

  8. Course Director Disclosures John Bartlett, MD Consulting Agreements: Johnson & Johnson; Tibotec; Merck & Co. Speakers' Bureau/Honorarium Agreements: Abbott Labs, Merck & Co. Financial Interests/Stock Ownership: None Other Financial or Material Support: DSMB; Tibotec Cal Cohen, MD Sources of Funding for Research: Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Roche; Pfizer; Tibotec; Merck; Boehringer Ingelheim; Panacos, Tobira, Myriad. Consulting Agreements: Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Pfizer; Tibotec, Boehringer Ingelheim; Panacos. Speakers' Bureau/Honorarium Agreements: Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Pfizer; Tibotec; Virco Financial Interests/Stock Ownership: None. Other: ViralEd, LLC.

  9. Discussant Disclosures • Cal Cohen, MD • Sources of Funding for Research: Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Roche; Pfizer; Tibotec; Merck; BoehringerIngelheim; Panacos, Tobira, Myriad. • Consulting Agreements: Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Pfizer; Tibotec, BoehringerIngelheim; Panacos. • Speakers' Bureau/Honorarium Agreements: Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Pfizer; Tibotec; Virco • Financial Interests/Stock Ownership: None. • Other: ViralEd, LLC • Ian Frank, MD • Grant Research: Merck & Co.; Bavarian Nordic; Tibotec • Consulting Agreements: BMS; GSK; Pfizer; Gilead Sciences; Tibotec; Abbott Labs • Speakers' Bureau/Honorarium Agreements: BMS; GSK; Pfizer; Gilead Sciences; Tibotec; Abbott Labs • Financial Interests/Stock Ownership: None • Other Financial or Material Support: None • This presentation will include information on studies and data presented at the 16th CROI involving off-label uses of efavirenz, tenofovir, emtricitabine, atazanavir, raltegravir, interleukin-2, GS-9350, SPI-452 and rosiglitazone.

  10. The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.

  11. Topics When to Start Preferred NRTIs Switching ARVs in Virologically Suppressed Patients Significance of ARV Pharmacokinetics Studies to Know

More Related